Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
289893-25-0
|
| gptkbp:chemicalClass |
benzylamine derivative
hydroxyalkylamine |
| gptkbp:developedBy |
treatment of neurodegenerative diseases
|
| gptkbp:developer |
Orphazyme A/S
|
| gptkbp:EMAStatus |
not approved
|
| gptkbp:hasMolecularFormula |
C17H25ClN2O
|
| gptkbp:hasSMILES |
CC(CO)N(C)Cc1ccc(cc1OC)OC.Cl
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
arimoclomol
|
| gptkbp:investigatedBy |
gptkb:Niemann-Pick_disease_type_C
amyotrophic lateral sclerosis scleroderma inclusion body myositis |
| gptkbp:IUPACName |
N-(2-hydroxypropyl)-3,4-dimethoxy-N-methylbenzylamine hydrochloride
|
| gptkbp:mechanismOfAction |
amplifies heat shock protein expression
|
| gptkbp:molecularWeight |
324.85 g/mol
|
| gptkbp:PubChem_CID |
DB12411
CHEMBL2103882 9941572 |
| gptkbp:regulates |
not approved
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
BRX-220
BRX-345 N-(2-hydroxypropyl)-3,4-dimethoxy-N-methylbenzylamine |
| gptkbp:bfsParent |
gptkb:Orphazyme
|
| gptkbp:bfsLayer |
8
|